Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity

Alexander I. Fridman, Sergei A. Matveev, Natalia I. Agalakova, Olga V. Fedorova, Edward Lakatta, Alexei Y. Bagrov

Research output: Contribution to journalArticle

Abstract

Background. A reduced cardiac output in chronic heart failure (CHF) evokes renal NaCl and water retention, and, therefore, activates mechanisms promoting natriuresis. Atrial natriuretic peptide (ANP) is one such factor. We hypothesized that another NaCl sensitive endogenous natriuretic factor, i.e., marinobufagenin (MBG), a specific ligand of the α-1 subunit of Na/K ATPase (the main kidney isoform) and also a vasoconstrictor and cardiotonic substance, would be elevated in CHF patients in a graded manner with the severity of CHF. Methods and results. We measured the plasma levels of MBG, α-hANP, ouabain-like compound (OLC) and left ventricular (LV) volumes and ejection fraction in 23 consecutive hypertensive male patients with CHF. Plasma MBG levels exhibited progressive increases (0.59 ± 0.15, 1.08 ± 0.20, 1.35 ± 0.17 and 1.88 ± 0.05 nmol/l NYHA 1-4, respectively) and paralleled the changes of α-hANP. Conversely, plasma OLC did not exhibit such increases. Plasma MBG correlated with α-hANP (r = 0.82; P < 0.0001). Both MBG and α-hANP correlated with LV systolic (r = 0.55 and r = 0.47; P < 0.01) diameter and inversely with ejection fraction (r = -0.73 and r = -0.60; P < 0.01). OLC did not exhibit correlations with α-hANP or LV volumes, but positively correlated with systolic brachial blood pressure and with pulse pressure. Conclusions. In CHF, MBG exhibits progressive increases similar to ANP, varies with CHF severity and correlates with LV systolic function. We hypothesize, that, in CHF, the concurrent production of these two natriuretic hormones, a vasorelaxant, ANP, and a vasoconstrictor, MBG, potentiate each other's natriuretic effects, but may offset their vasoactive actions.

Original languageEnglish (US)
Pages (from-to)1189-1194
Number of pages6
JournalJournal of Hypertension
Volume20
Issue number6
DOIs
StatePublished - Jun 2002
Externally publishedYes

Fingerprint

Sodium-Potassium-Exchanging ATPase
Heart Failure
Ligands
Natriuretic Agents
Atrial Natriuretic Factor
Ouabain
Vasoconstrictor Agents
Blood Pressure
Cardiotonic Agents
Kidney
Natriuresis
marinobufagenin
Vasodilator Agents
Left Ventricular Function
Cardiac Output
Stroke Volume
Protein Isoforms
Arm
Water

Keywords

  • Bufanolides
  • Heart failure
  • Na(+)-K(+)-exchanging ATPase
  • Natriuretic peptides
  • Ouabain
  • Steroids

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine

Cite this

Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. / Fridman, Alexander I.; Matveev, Sergei A.; Agalakova, Natalia I.; Fedorova, Olga V.; Lakatta, Edward; Bagrov, Alexei Y.

In: Journal of Hypertension, Vol. 20, No. 6, 06.2002, p. 1189-1194.

Research output: Contribution to journalArticle

Fridman, Alexander I. ; Matveev, Sergei A. ; Agalakova, Natalia I. ; Fedorova, Olga V. ; Lakatta, Edward ; Bagrov, Alexei Y. / Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. In: Journal of Hypertension. 2002 ; Vol. 20, No. 6. pp. 1189-1194.
@article{02e37934298a418a884ce8e209a247e3,
title = "Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity",
abstract = "Background. A reduced cardiac output in chronic heart failure (CHF) evokes renal NaCl and water retention, and, therefore, activates mechanisms promoting natriuresis. Atrial natriuretic peptide (ANP) is one such factor. We hypothesized that another NaCl sensitive endogenous natriuretic factor, i.e., marinobufagenin (MBG), a specific ligand of the α-1 subunit of Na/K ATPase (the main kidney isoform) and also a vasoconstrictor and cardiotonic substance, would be elevated in CHF patients in a graded manner with the severity of CHF. Methods and results. We measured the plasma levels of MBG, α-hANP, ouabain-like compound (OLC) and left ventricular (LV) volumes and ejection fraction in 23 consecutive hypertensive male patients with CHF. Plasma MBG levels exhibited progressive increases (0.59 ± 0.15, 1.08 ± 0.20, 1.35 ± 0.17 and 1.88 ± 0.05 nmol/l NYHA 1-4, respectively) and paralleled the changes of α-hANP. Conversely, plasma OLC did not exhibit such increases. Plasma MBG correlated with α-hANP (r = 0.82; P < 0.0001). Both MBG and α-hANP correlated with LV systolic (r = 0.55 and r = 0.47; P < 0.01) diameter and inversely with ejection fraction (r = -0.73 and r = -0.60; P < 0.01). OLC did not exhibit correlations with α-hANP or LV volumes, but positively correlated with systolic brachial blood pressure and with pulse pressure. Conclusions. In CHF, MBG exhibits progressive increases similar to ANP, varies with CHF severity and correlates with LV systolic function. We hypothesize, that, in CHF, the concurrent production of these two natriuretic hormones, a vasorelaxant, ANP, and a vasoconstrictor, MBG, potentiate each other's natriuretic effects, but may offset their vasoactive actions.",
keywords = "Bufanolides, Heart failure, Na(+)-K(+)-exchanging ATPase, Natriuretic peptides, Ouabain, Steroids",
author = "Fridman, {Alexander I.} and Matveev, {Sergei A.} and Agalakova, {Natalia I.} and Fedorova, {Olga V.} and Edward Lakatta and Bagrov, {Alexei Y.}",
year = "2002",
month = "6",
doi = "10.1097/00004872-200206000-00032",
language = "English (US)",
volume = "20",
pages = "1189--1194",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity

AU - Fridman, Alexander I.

AU - Matveev, Sergei A.

AU - Agalakova, Natalia I.

AU - Fedorova, Olga V.

AU - Lakatta, Edward

AU - Bagrov, Alexei Y.

PY - 2002/6

Y1 - 2002/6

N2 - Background. A reduced cardiac output in chronic heart failure (CHF) evokes renal NaCl and water retention, and, therefore, activates mechanisms promoting natriuresis. Atrial natriuretic peptide (ANP) is one such factor. We hypothesized that another NaCl sensitive endogenous natriuretic factor, i.e., marinobufagenin (MBG), a specific ligand of the α-1 subunit of Na/K ATPase (the main kidney isoform) and also a vasoconstrictor and cardiotonic substance, would be elevated in CHF patients in a graded manner with the severity of CHF. Methods and results. We measured the plasma levels of MBG, α-hANP, ouabain-like compound (OLC) and left ventricular (LV) volumes and ejection fraction in 23 consecutive hypertensive male patients with CHF. Plasma MBG levels exhibited progressive increases (0.59 ± 0.15, 1.08 ± 0.20, 1.35 ± 0.17 and 1.88 ± 0.05 nmol/l NYHA 1-4, respectively) and paralleled the changes of α-hANP. Conversely, plasma OLC did not exhibit such increases. Plasma MBG correlated with α-hANP (r = 0.82; P < 0.0001). Both MBG and α-hANP correlated with LV systolic (r = 0.55 and r = 0.47; P < 0.01) diameter and inversely with ejection fraction (r = -0.73 and r = -0.60; P < 0.01). OLC did not exhibit correlations with α-hANP or LV volumes, but positively correlated with systolic brachial blood pressure and with pulse pressure. Conclusions. In CHF, MBG exhibits progressive increases similar to ANP, varies with CHF severity and correlates with LV systolic function. We hypothesize, that, in CHF, the concurrent production of these two natriuretic hormones, a vasorelaxant, ANP, and a vasoconstrictor, MBG, potentiate each other's natriuretic effects, but may offset their vasoactive actions.

AB - Background. A reduced cardiac output in chronic heart failure (CHF) evokes renal NaCl and water retention, and, therefore, activates mechanisms promoting natriuresis. Atrial natriuretic peptide (ANP) is one such factor. We hypothesized that another NaCl sensitive endogenous natriuretic factor, i.e., marinobufagenin (MBG), a specific ligand of the α-1 subunit of Na/K ATPase (the main kidney isoform) and also a vasoconstrictor and cardiotonic substance, would be elevated in CHF patients in a graded manner with the severity of CHF. Methods and results. We measured the plasma levels of MBG, α-hANP, ouabain-like compound (OLC) and left ventricular (LV) volumes and ejection fraction in 23 consecutive hypertensive male patients with CHF. Plasma MBG levels exhibited progressive increases (0.59 ± 0.15, 1.08 ± 0.20, 1.35 ± 0.17 and 1.88 ± 0.05 nmol/l NYHA 1-4, respectively) and paralleled the changes of α-hANP. Conversely, plasma OLC did not exhibit such increases. Plasma MBG correlated with α-hANP (r = 0.82; P < 0.0001). Both MBG and α-hANP correlated with LV systolic (r = 0.55 and r = 0.47; P < 0.01) diameter and inversely with ejection fraction (r = -0.73 and r = -0.60; P < 0.01). OLC did not exhibit correlations with α-hANP or LV volumes, but positively correlated with systolic brachial blood pressure and with pulse pressure. Conclusions. In CHF, MBG exhibits progressive increases similar to ANP, varies with CHF severity and correlates with LV systolic function. We hypothesize, that, in CHF, the concurrent production of these two natriuretic hormones, a vasorelaxant, ANP, and a vasoconstrictor, MBG, potentiate each other's natriuretic effects, but may offset their vasoactive actions.

KW - Bufanolides

KW - Heart failure

KW - Na(+)-K(+)-exchanging ATPase

KW - Natriuretic peptides

KW - Ouabain

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=0036591601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036591601&partnerID=8YFLogxK

U2 - 10.1097/00004872-200206000-00032

DO - 10.1097/00004872-200206000-00032

M3 - Article

C2 - 12023690

AN - SCOPUS:0036591601

VL - 20

SP - 1189

EP - 1194

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 6

ER -